Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended? | Zendy

George Galyfos | Zendy; Argyri Sianou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cilostazol for Secondary Prevention of Stroke: Should the Guidelines Perhaps Be Extended?

Author(s) -

George Galyfos,

Argyri Sianou

Publication year - 2017

Publication title -

vascular specialist international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.316

H-Index - 3

eISSN - 2288-7989

pISSN - 2288-7970

DOI - 10.5758/vsi.2017.33.3.89

Subject(s) - cilostazol , medicine , intermittent claudication , intensive care medicine , stroke (engine) , arterial disease , secondary prevention , disease , claudication , aspirin , vascular disease , mechanical engineering , engineering

Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol's action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research